Co-infection 2018 – Presentations

 

Pre-workshop Educational Course
Wednesday 16 May

  

 

8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, British Columbia, Canada.
HCV in 2018

Jürgen Rockstroh, MD, University of Bonn, Germany
  

Marion Peters, MD

HBV: diagnostics, management and screening
Marion Peters, MD, Mount Sinai Medical Centre, New York, NY, USA

  Berenguer, Juan 2017 120Liver care in HIV - management of abnormal LFTs
Juan Berenguer, MD, PHD, Hospital General Universitario Gregorio Marañón, Madrid, Spain
  Macias Sanchez, Juan 2018NAFLD: diagnostics, management and screening
Juan Macias, MD, PhD, Hospital de Valme, Seville, Spain
  Peters, Marion 2010_120
Fibrosis Markers and Cirrhosis management in HIV patients

Marion Peters, MD, Mount Sinai Medical Centre, New York, NY, USA
  Session 1: Management of Hepatitis C - part 1
  DAA: will generics change the landscape?
Sabela Lens, MD, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain (Not available)
  Response to sofosbuvir/ledipasvir for 8 or 12 weeks in HCV-monoinfected and HIV/HCV-coinfected patients in clinical practice
Anaïs Corma
  Real life results of grazoprevir/elbasvir inHCV-infected pwid: the zepalive study
Juan Macias
  Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life
Luis M. Real
  A comparison of single and multiple tablet regimens for the treatment of HCV infection among HIV co-infected individuals
Astou Thiam
 

Thursday 17 May 2018

  Session 2: Management of Hepatitis C - part 2
  Bruno, Raffaele 2016_120x160
HCV care after cure

Raffaele Bruno, MD, University of Pavia, Italy
  Merchante, Nicolas 2017 120
Long-term changes of liver stiffness after the use of all oral DAA regimens

Nicolas Merchante
  Follow-up of sustained virological responders with hepatits C/HIV co-infection and advanced liver disease
Cristina Soeiro
 Session 3: Management of Hepatitis B - part 1
  Lacombe, Karine 2016_120x160
HBV managment in HIV patients
 
Karine Lacombe, MD, PhD, Hôpital Saint Antoine Paris, France
  Buti, Maria 2011
HBV Novel Therapies

Maria Buti, MD,PHD Hospital Universitario Valle Hebron, Barcelona, Spain
 Session 5: Management of Hepatitis B - part 2
  

Debate: TDF vs. TAF in HBV management

Nelson, Mark 2012_120TAF
Mark Nelson, MD, Chelsea and Westminster Hospital, London, UK

 

 

Dieterich, Douglas 2011_120TDF
Douglas Dieterich, MD,
Mount Sinai Medical Centre, New York, NY, USA

 

  Case on HEV
Antonio, Rivero-Juarez, PhD, Hospital Universitario Reina Sofia, Cordoba, Spain
 Session 6: NAFLD and HIV
  Macias Sanchez, Juan 2018NAFLD in HIV- infected patients
Juan Macías, MD, PhD, Hospital de Valme, Seville, Spain
  Expression of immunological markers in inflammatory infiltrate cells of liver tissue in patients with HIV/HCV coinfection
Natalia Matsiyeuskaya
  Merchante, Nicolas 2017 120Failure rate of ultrasound surveillance of hepatocellular carcinoma in HIV-infected patients
Nicolas Merchante
  CD4-T cell and metabolic changes after DAAs: a multicenter case-control study
Laura Ambra Nicolini (Not available)
  

Friday 18 May 2018

 Session 7: Fibrosis markers in liver disease
  Merchante, Nicolas 2017 120The role of Fibroscan: pre and post SVR
Nicolás Merchante, MD, Hospital de Valme, Seville, Spain
  

Roundtable Discussion: Hepatitis A in HIV: the French, Italian, and Spanish Perspective

Italian Perspective
Andrea Lombardi, MD, Infectious and Tropical Diseases Unit, IRCCS “San Matteo” and University of Pavia, Pavia, Italy

Massimo Puoti, MD, Niguarda Ca'Granda Hospital, Milan, Italy

Spanish Perspective
Luz Martín-Carbonero, MD, PhD, Hospital Universitario La Paz, Madrid, Spain

  Hepatitis C reinfection after sustained virological response in HIV/HCV coinfected patients
Fabio Andre Videira Santos